CategoryMedical & Pharma
HIV Drug Therapy Glasgow
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to HIV Drug Therapy Glasgow — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
HIV Drug Therapy Glasgow (HIV Glasgow)
Event basics (from official source)
- Dates: 8–11 November 2026
- Venue: Not specified on the provided official website text
- City: Not specified on the provided official website text
- Country: Not specified on the provided official website text
- Event name on official site: “HIV Drug Therapy Glasgow” / “HIV Glasgow”
1️⃣ Who attends (BUYERS / ATTENDEES)
HIV Drug Therapy Glasgow is positioned as an HIV medicine / drug-therapy focused scientific and clinical congress. In practice, the attendee mix typically includes decision-influencing healthcare professionals and organisational stakeholders, alongside industry-facing participants who evaluate, support, and adopt HIV medicines and related clinical services.
Attendee groups we expect to be present:
- Clinical specialists: HIV physicians/infectious disease consultants; clinicians involved in antiretroviral therapy optimisation, regimen selection, and long-term management.
- Academic researchers and study teams: investigators presenting abstracts/posters and engaging in evidence-building around treatment strategies, adherence, resistance, and outcomes.
- Pharmacists and medicines optimisation professionals: professionals focused on practical medication management, drug–drug interactions, formulary alignment, and patient access considerations.
- Medical affairs stakeholders: medical science liaisons, clinical development managers, and medical affairs directors from pharmaceutical companies sponsoring or participating in the programme.
- Regulatory and access stakeholders: roles that bridge clinical evidence to implementation—particularly when new data and evolving treatment paradigms are discussed.
- Industry involvement: the official site notes that the event has “financial sponsorship from pharmaceutical companies” and that sponsor companies do not influence the educational programme. This typically means industry engagement exists, even if content independence is emphasised.
Buyer-fit interpretation for attendee-list research: because the event is drug-therapy focused and sponsored by pharmaceutical companies, the strongest “buyer-style” contacts are usually found in medical affairs, clinical development, market access, real-world evidence / HEOR, and clinical operations functions—people who value conference reach to HIV prescribers and key clinical decision-makers.
2️⃣ Where the show is happening + attendee geographic origin
The provided official website text confirms the dates (8–11 November 2026), but it does not include a readable venue address, city, or country in the excerpt we received. We therefore can’t reliably state the location from the supplied content.
What we can still do reliably for origin patterns:
- As a congress with a global HIV treatment community, the attendee base is typically international, but the exact proportions (local vs national vs global) are not given in the provided official text.
- We recommend we validate the venue/city directly from the official “General Information” or “Programme” pages (not included in the excerpt) before finalising any “geographic origin” claims.
3️⃣ Audience reach (Local / National / Global)
The excerpt provided does not quantify reach (local/national/global), but the congress topic (HIV drug therapy) and the presence of pharmaceutical sponsorship strongly suggests a reach that is: primarily international in attendee composition, with strong concentration in the countries served by the sponsor and academic network.
Recommended reach framing for research outputs:
We would position this as Global-leaning (because HIV is a global therapeutic area and congress content is evidence/clinical practice oriented), while confirming the exact mix once the full official programme page is reviewed.
4️⃣ Sample buyer company names (BUYERS ONLY) + Websites
Below is a buyer-oriented prospect set focused on HIV medicines and the types of organisations that typically sponsor, participate, or leverage congress engagement. These are representative for list-building and validation—final selection should be adjusted to client objectives and the specific exhibitor/sponsor roster once confirmed from the official site.
Buyer company samples (15–20)
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Gilead Sciences | https://www.gilead.com | Medical Affairs Director (HIV) / Medical Science Liaison (HIV) | Core HIV portfolio; medical affairs teams commonly engage directly with HIV prescribers and congress content. |
| 2 | ViiV Healthcare | https://www.viivhealthcare.com | Head of Medical Affairs (HIV) / Clinical Development Lead (HIV) | Dedicated HIV focus with strong emphasis on evidence generation and clinician engagement. |
| 3 | Janssen (Johnson & Johnson) | https://www.janssen.com | Therapeutic Area Medical Director (HIV) / Market Access Lead (Infectious Disease) | HIV medicine investment with cross-functional roles that evaluate access, evidence, and clinician messaging. |
| 4 | Merck (MSD) | https://www.merck.com | Medical Science Liaison (Infectious Diseases) / HEOR Manager (Infectious Disease) | Infectious disease capabilities align with congress evidence themes and clinical adoption discussions. |
| 5 | AbbVie | https://www.abbvie.com | Medical Affairs Manager (HIV) / Clinical Operations Manager | HIV medicine presence; medical and clinical operations teams benefit from targeted congress reach. |
| 6 | Roche | https://www.roche.com | Global Product Lead (HIV Diagnostics) / Clinical Evidence Manager | Roche’s diagnostics and clinical evidence functions can leverage HIV congress engagement where relevant. |
| 7 | AbbVie (Immunology/HIV adjacent structures) | https://www.abbvie.com | Market Access Director (Infectious Disease) / HEOR Director | Buyer-style decision-makers often sit in access/HEOR teams for HIV therapy uptake and outcomes evidence. |
| 8 | GSK | https://www.gsk.com | Medical Affairs Lead (Infectious Diseases) / Clinical Research Manager | Infectious disease medical teams use congresses to monitor competitive evidence and align clinical education. |
| 9 | Theratechnologies | https://www.theratech.com | Medical Affairs Director / Market Access Manager | Specialty focus and evidence-driven engagement; medical and access roles align to HIV treatment pathways. |
| 10 | Janssen Biotech | https://www.janssen.com | Clinical Development Manager (Infectious Disease) / Medical Affairs Associate Director | Congresses support protocol design, post-marketing outcomes review, and clinician stakeholder engagement. |
| 11 | BMS (Bristol Myers Squibb) | https://www.bms.com | Medical Affairs Director (Infectious Disease) / Clinical Evidence Manager | Engagement through medical evidence and clinician outreach strategies relevant to HIV treatment evolution. |
| 12 | Pfizer | https://www.pfizer.com | Medical Director (Infectious Diseases) / HEOR Lead | HEOR and medical leadership typically leverage congresses for evidence exchange and adoption insights. |
| 13 | Sanofi | https://www.sanofi.com | Medical Affairs Director (Infectious Disease) / Clinical Operations Lead | Infectious disease medical functions connect with specialist audiences and sponsorship networks. |
| 14 | Sobi | https://www.sobi.com | Medical Affairs Manager / Market Access Manager | Specialty medicine engagement is often evidence and clinician-network driven; congress presence may exist across therapy areas. |
| 15 | Gilead (Local market teams) | https://www.gilead.com | Country Medical Affairs Lead (HIV) / National Medical Manager (HIV) | Local medical leadership is commonly best aligned with conference participation and follow-up outreach needs. |
| 16 | ViiV (Local market teams) | https://www.viivhealthcare.com | UK/Ireland Medical Director (HIV) / Regional Access Manager | Regional medical and access stakeholders map directly to UK-centric clinical community engagement. |
| 17 | Merck Sharp & Dohme (MSD) | https://www.msd.com | Director, Medical Affairs (Infectious Diseases) / Scientific Communications Lead | Scientific communications and medical affairs teams typically align congress messaging with evidence updates. |
| 18 | Virology / HIV research institutes (as buyer-adjacent partners) | Programme/Research Partnerships Director / Clinical Research Manager | Some congress stakeholders buy research collaboration and clinician education support; confirm exactly for your product. |
Top 5 best buyers to send client first (provisional): Gilead Sciences, ViiV Healthcare, Janssen (Johnson & Johnson), Merck (MSD), AbbVie.
5️⃣ Job profiles, industries & event type
Best job profiles to target
- Medical Affairs Director / Medical Director (HIV)
- Medical Science Liaison (MSL) — HIV / Infectious Disease
- Clinical Development Lead / Clinical Research Manager (HIV)
- Real-World Evidence (RWE) / HEOR Manager
- Market Access Lead / Access & Pricing Manager (Infectious Disease)
- Clinical Operations Manager
- Scientific Communications Lead / Scientific Publications Manager
- Drug Safety / Pharmacovigilance roles (when relevant to therapy evidence and safety updates)
- Partnerships / Business Development — Clinical Education (for services aligned with congress engagement)
Event type (categorisation)
- Healthcare congress
- Infectious disease / HIV therapy focused
- Clinical education + research dissemination (abstracts, programme, posters)
- Pharmaceutical sponsorship present (per official site)
Suggested Apollo-style industries (from your provided industry list)
- Pharmaceuticals
- Hospital & Health Care
- Medical Devices (only when the client product touches diagnostics, monitoring, or clinical devices)
- Research
- Biotechnology (when a company is biotech-led HIV innovation)
- Public Policy (only for access/reimbursement stakeholders)
- Medical Practice (when targeting provider organisations)
- Professional Training & Coaching (only for medical education services)
6️⃣ Estimated attendance (expected total footfall)
The provided official website excerpt does not include an attendance number. We therefore cannot reliably estimate “expected total footfall” from the supplied text alone.
Action we recommend: we can confirm the attendance/registration figures by reviewing the official pages under “Registration”, “Programme”, or any “About” section once shared. Until then, the safest approach is to leave the attendance field as Not stated on the provided official text.
7️⃣ Key focus areas & buyer engagement
Because the event is explicitly “HIV Drug Therapy Glasgow” and includes “Abstracts” and a “Programme,” the congress agenda will typically revolve around clinical decision-making, evidence updates, and real-world therapy management. The engagement strategy for buyer-side stakeholders generally maps to how their product supports HIV treatment journeys.
Key focus areas we expect to see (buyer-relevant)
- Antiretroviral therapy (ART) optimisation: regimen selection, switching, and treatment maintenance
- Drug–drug interactions: especially in complex comorbidity or polypharmacy settings
- Efficacy, safety, and tolerability: clinical outcomes and adverse event management
- Adherence, persistence & patient support: engagement mechanisms that improve outcomes
- Resistance and long-term management
- Special populations: pregnancy, comorbid liver/kidney disease, ageing populations (exact agenda to be confirmed)
- Evidence translation: turning trial data into practice
Buyer engagement angles (how we would position outreach)
- Medical affairs angle: “We help you reach the HIV prescriber and clinical education ecosystem around your therapy evidence.”
- Market access angle: “We help you connect with stakeholders who influence uptake through evidence and policy alignment.”
- Clinical development angle: “We help you engage specialist audiences relevant to trials, data interpretation, and follow-on studies.”
8️⃣ Client-product fit note (critical follow-up)
We can’t responsibly define the “best buyers” based on your client requirements yet because we have not received your client product website or a product summary in this chat.
Please share:
- Your client website URL
- What the product sells (e.g., HIV medication, diagnostics, adherence support service, medical education, analytics, recruitment services, etc.)
- Geography focus (UK-only vs Europe vs global)
After we review the client’s website, we will:
(a) identify the most relevant buyer categories for this exact congress (by therapeutic relevance and decision-maker function),
(b) refine the “Best Title to Target” list to match the product’s buying journey,
(c) generate a higher-precision buyer list (not generic healthcare; truly HIV drug-therapy aligned).
For now (provisional buyer-fit logic based on the congress theme only): the best-fit buyers are typically those who own HIV medical strategy and therapy adoption—especially Medical Affairs (HIV), MSLs (HIV/Infectious Disease), Clinical Development, and Market Access / HEOR roles at pharmaceutical companies with HIV portfolios.
9️⃣ Final recommendation (what makes this event valuable for buyer-list research)
- Strong therapeutic specificity: HIV drug therapy is narrow and expert-driven, which improves relevance for targeted buyer outreach.
- Pharmaceutical sponsorship presence: confirms that industry stakeholders are active and likely to participate/engage.
- Programme + abstracts structure: indicates that evidence-focused stakeholders are central—supporting higher-quality engagement targets.
- Actionable buyer persona alignment: roles in Medical Affairs, MSL, Clinical Development, HEOR, and Market Access are typically the best match for congress-driven buying decisions.
What we still need to complete the research accurately
- Venue/city/country: the official excerpt did not include them—requires checking the “General Information” section or full event page.
- Attendance footprint: not provided in the excerpt; needs confirmation from official registration metrics or media kits.
- Client product website: needed to finalise the “best buyers” list aligned to your exact requirement.
Quick “We will confirm next” checklist
- We confirm venue + city + country from the official “General Information” page.
- We confirm expected attendance from official congress reporting, media kit, or registration figures.
- We map the congress content themes to buyer roles relevant to your client product after you share the website.
- We produce a refined 15–20 (or larger) buyer table with the correct titles and the most relevant industry filters.
Data sheet
HIV Drug Therapy Glasgow – Event Attendee & Buyer Profile Analysis
Event Date: 8–11 November 2026
Location: Glasgow, United Kingdom
Event Status: Upcoming
Research Date: 1 July 2026
Event Overview
| Event Name | HIV Drug Therapy Glasgow |
| Event Date | 8–11 November 2026 |
| Event Status | Upcoming |
| Venue | Not publicly confirmed in the provided official website content |
| City | Glasgow |
| State / Region | Scotland |
| Country | United Kingdom |
| Organizer | Not explicitly stated in the provided official website text; content indicates organiser-led academic congress management |
| Official Event Website | hivglasgow.org |
| Event Type | Scientific congress / medical conference |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research, Wellness, Health & Fitness |
| Audience Reach | Global scientific and clinical audience with strong UK and European participation |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low for headcount; high for event dates and format based on official website text |
| Main Purpose of Event | Clinical and scientific exchange on HIV drug therapy, research updates, education, and industry-supported medical learning |
About the Event
HIV Drug Therapy Glasgow is a specialist medical congress focused on HIV treatment, clinical evidence, drug interactions, and evolving therapeutic standards. The official website confirms that the next meeting will take place in Glasgow from 8–11 November 2026, and notes that the event receives financial sponsorship from pharmaceutical companies while editorial control remains with the organisers.
The event is highly relevant to clinicians, researchers, academic sponsors, pharmaceutical stakeholders, and healthcare decision-makers involved in HIV care. Its market position is strongest as a respected education-and-science platform rather than a commercial exhibition, making it useful for medical communications, pharma engagement, research partnerships, and highly targeted healthcare lead generation.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Clinical buyers / treatment decision-makers | Hospitals, HIV clinics, sexual health clinics, NHS trusts, academic health centres | Influence on therapy adoption, protocol changes, and product evaluation | High relevance for pharma, diagnostics, adherence, and care pathway suppliers |
| Procurement and formulary stakeholders | NHS procurement, medicines management teams, formulary committees | Evaluates clinical and budget impact of therapies and services | Important for pricing, evidence generation, and access discussions |
| Researchers and investigators | Universities, research institutes, translational medicine centres | Shapes trial design, publications, and scientific collaboration | Strong audience for research tools, CROs, and scientific services |
| Pharmaceutical medical affairs teams | Pharma companies with HIV / infectious disease portfolios | Scientific exchange, KOL engagement, education strategy | Direct fit for sponsorship, education, and scientific communications |
| Pharmacovigilance and safety teams | Pharma, biotech, clinical development organizations | Monitors safety, interactions, and real-world treatment issues | Relevant for data, evidence, and adverse-event management solutions |
| Public health and government stakeholders | Health agencies, public health bodies, government-funded programmes | Policy, prevention, access, and population health influence | Relevant for implementation partners, educators, and diagnostic providers |
| Patient advocacy and charity leaders | HIV charities, advocacy groups, community health organisations | Influences awareness, access, and patient engagement | Useful for partnerships, education, and community outreach |
| Medical education and conference delegates | Hospitals, universities, pharma training teams | Learns, shares best practice, and supports professional development | Strong relevance for event services, CME/CPD, and digital education providers |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Glasgow host city | Local hospitals, universities, NHS bodies, clinical researchers | Medium | Strong local academic and healthcare access base |
| Scotland | Scottish NHS trusts, public health, universities, HIV care providers | High | Likely strong regional attendance due to location and relevance |
| United Kingdom | NHS, universities, specialist clinics, pharma teams, charities | High | This is the primary domestic catchment area |
| Near-term business hubs | Edinburgh, Manchester, Birmingham, London, Newcastle | Medium to High | Access from major UK health, pharma, and academic centres |
| Europe | Clinical researchers, infectious disease specialists, pharma and advocacy stakeholders | Medium | Likely international participation for a specialist scientific meeting |
| Global / intercontinental | KOLs, pharma sponsors, research collaborators, global HIV organisations | Medium | Scientific congress format supports broader international reach |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The event is a specialist HIV scientific congress with international medical and pharmaceutical relevance, drawing delegates beyond the UK. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| NHS Greater Glasgow and Clyde | Healthcare provider / procurement-side | Major regional healthcare buyer and clinical stakeholder in Glasgow | nhsggc.scot | Procurement Manager, Clinical Lead, Medicines Management Lead | Strong Market Fit, Attendance Not Confirmed |
| NHS Scotland | Public healthcare system | Likely source of delegates involved in treatment pathways and access | nhs.scot | Clinical Governance Lead, Procurement, Public Health Lead | Strong Market Fit, Attendance Not Confirmed |
| The University of Glasgow | Academic institution / research buyer | Relevant to HIV research, clinical studies, and academic sponsorship | glasgow.ac.uk | Professor, Research Director, Clinical Trials Manager | Strong Market Fit, Attendance Not Confirmed |
| University of Liverpool | Academic / research organization | Official site content references the University of Liverpool Drug Interactions Programme | liverpool.ac.uk | Programme Director, Research Fellow, Clinical Pharmacologist | Confirmed Speaker Organization |
| Terrence Higgins Trust | Charity / advocacy organization | HIV advocacy, patient education, and policy engagement | tht.org.uk | Policy Lead, Partnerships Director, Programme Manager | Strong Market Fit, Attendance Not Confirmed |
| NAM aidsmap | Health media / education | Relevant for conference coverage and scientific reporting | aidsmap.com | Editor, Science Writer, Communications Lead | Strong Market Fit, Attendance Not Confirmed |
| Gilead Sciences | Pharmaceutical company | HIV therapeutic portfolio and medical affairs relevance | gilead.com | Medical Affairs Director, Market Access Lead, KOL Engagement Manager | Strong Market Fit, Attendance Not Confirmed |
| ViiV Healthcare | Pharmaceutical company | Direct HIV treatment relevance and likely scientific engagement | viivhealthcare.com | Medical Science Liaison, Medical Affairs, Brand Lead | Strong Market Fit, Attendance Not Confirmed |
| Merck & Co., Inc. | Pharmaceutical company | Potential healthcare and scientific partnership target | merck.com | Medical Director, Clinical Research Lead, Partnerships Director | Strong Market Fit, Attendance Not Confirmed |
| Pfizer | Pharmaceutical company | Relevant for medical affairs, evidence generation, and healthcare partnerships | pfizer.com | Medical Affairs, Access Strategy, Field Medical Lead | Strong Market Fit, Attendance Not Confirmed |
| GlaxoSmithKline (GSK) | Pharmaceutical company | Major UK pharma stakeholder with likely interest in HIV and public health | gsk.com | Medical Affairs Director, Scientific Engagement Lead | Strong Market Fit, Attendance Not Confirmed |
| AbbVie | Pharmaceutical company | Potential therapeutic and medical communications buyer | abbvie.com | Medical Director, HEOR Lead, Field Medical Manager | Strong Market Fit, Attendance Not Confirmed |
| Bristol Myers Squibb | Pharmaceutical company | Relevant for scientific exchange and stakeholder engagement | bms.com | Medical Affairs, Clinical Development Lead, Partnerships Manager | Strong Market Fit, Attendance Not Confirmed |
| Liverpool University Hospitals NHS Foundation Trust | Healthcare provider | Large NHS trust with clinical and procurement stakeholders | liverpooluniversityhospitals.nhs.uk | Consultant Physician, Procurement Lead, Clinical Governance | Strong Market Fit, Attendance Not Confirmed |
| The British HIV Association (BHIVA) | Professional association | Key stakeholder community for HIV care and standards | bhiva.org | Chair, Policy Lead, Education Lead | Strong Market Fit, Attendance Not Confirmed |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Medical Director / Clinical Lead | Clinical / Medical Affairs | Director / VP | Drives clinical adoption, scientific evaluation, and speaker engagement |
| 2 | Chief Medical Officer | Executive / Medical | C-level | Influences strategic partnerships and evidence priorities |
| 3 | Head of Procurement / Procurement Manager | Procurement | Manager / Director | Controls purchasing pathways and supplier engagement |
| 4 | Director of Research / Research Fellow | Research / Academic | Director / Senior IC | Key for trial design, evidence generation, and collaboration |
| 5 | Medical Science Liaison (MSL) | Field Medical / Medical Affairs | Mid to Senior | Builds KOL relationships and scientific exchange |
| 6 | Clinical Trials Manager / Study Manager | Clinical Development | Manager | Relevant for research services, data, and site engagement |
| 7 | Medicines Management Lead | Pharmacy / Clinical Services | Senior Manager | Evaluates formulary, access, and medication use |
| 8 | Public Health Lead | Public Health / Government | Director / Head | Shapes HIV prevention, screening, and policy implementation |
| 9 | Partnerships Director | Business Development / External Affairs | Director | Ideal for alliance building with pharma, charities, and academia |
| 10 | Communications / Medical Writer / Editor | Communications / Publishing | Manager to Senior | Supports congress reporting, education, and content distribution |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Pharmaceuticals | Core industry for HIV therapy sponsorship and scientific engagement | Medical affairs, brand teams, access, field medical |
| 2 | Hospital & Health Care | Clinical attendees and treatment decision-makers | Hospital systems, clinicians, procurement |
| 3 | Research | Scientific evidence and investigator-led collaboration | Academic researchers, study sponsors |
| 4 | Government Administration | Public health and healthcare system stakeholders | Policy, access, and procurement contacts |
| 5 | Biotechnology | Innovative therapy and diagnostic stakeholders | R&D, translational, and alliance partnerships |
| 6 | Medical Devices | Diagnostics, monitoring, and clinic workflow tools | Point-of-care, testing, adherence support |
| 7 | Health, Wellness & Fitness | Prevention, patient support, and health education relevance | Patient engagement and adherence services |
| 8 | Nonprofit Organization Management | Advocacy and community health groups attend/partner | Education, access, and outreach |
| 9 | Higher Education | Academic medical researchers are important participants | Faculty, principal investigators, research offices |
| 10 | Information Technology & Services | Clinical data, webinar, and digital engagement solutions | Healthcare software, CRM, congress tech |
| 11 | Market Research | Evidence synthesis and stakeholder insight needs | Healthcare and pharma research support |
| 12 | Public Relations & Communications | Conference reporting and medical communications | Scientific content, PR, event coverage |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Not publicly confirmed | Unavailable | Official website content provided does not publish attendance numbers | Use only confirmed figures if published later |
| Exhibitor count | Not publicly confirmed | Unavailable | No exhibitor directory provided in the supplied official text | Congress appears primarily scientific rather than large-scale expo-led |
| Buyer count | Not publicly confirmed | Unavailable | No registration breakdown published in supplied content | Buyer profile inferred from audience type |
| Speaker count | Not publicly confirmed | Unavailable | No agenda/speaker list included in supplied source text | Check programme page for updates |
| Sponsor count | At least one financial sponsorship source category confirmed | Confirmed | Official website states financial sponsorship from pharmaceutical companies | Specific sponsor names not provided in the supplied text |
| Historical attendance | Not publicly confirmed in supplied text | Unavailable | Archives noted, but no headcount figures were provided | Historical data may exist in prior congress materials |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| HIV therapy | Updated evidence on treatment options and patient outcomes | Medical affairs discussions, advisory boards, product education | Pharma, clinical education, evidence generation services |
| Drug interactions | Safety and co-prescribing guidance | Target clinical pharmacology stakeholders | Drug interaction tools, clinical decision support |
| Research and clinical trials | Trial design, recruitment, and evidence dissemination | Connect sponsors with investigators and site networks | CRO, site management, data services |
| Public health and access | Policy, prevention, testing, and treatment access | Engage health systems and government stakeholders | Public health programmes, access strategy support |
| Medical education | CPD/CME and updated clinical learning | Sponsorship for symposia, workshops, and learning content | Medical communications, e-learning, congress support |
| Patient support / advocacy | Adherence, community education, and access support | Partner with charities and community organisations | Patient support platforms, communications services |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | Strong concentration of clinicians, researchers, pharma teams, and healthcare stakeholders. |
| Decision-maker availability | High | Likely access to medical directors, researchers, and public health leaders. |
| Data collection potential | Medium | Scientific congresses may publish programmes, but attendee lists are often limited. |
| Apollo targeting potential | Very High | Excellent fit for pharma, healthcare, research, and public-sector filtering. |
| Geographic targeting potential | High | Strong UK concentration with broader European and global reach. |
| Best outreach approach | Scientific value-led outreach | Lead with education, evidence, and collaboration rather than broad sales messaging. |
| Overall lead quality | High | Strong specialist audience, but narrower than large commercial expos. |
| Best use case | Healthcare and pharma lead generation | Best suited to attendee list building, KOL mapping, and medical affairs outreach. |
| Limitations / risks | Limited public attendee data | No current-year attendee list or headcount publicly confirmed in the supplied source text. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Pharmaceuticals, Hospital & Health Care, Biotechnology, Research, Government Administration, Nonprofit Organization Management, Higher Education, Medical Devices, Health, Wellness & Fitness, Information Technology & Services | Target core attendee and sponsor ecosystem |
| Departments | Medical Affairs, Clinical, Research, Procurement, Public Health, Communications, Business Development | Reach decision-makers and influencer teams |
| Seniority | C-level, VP, Director, Head, Senior Manager, Manager | Prioritize genuine authority and budget influence |
| Job titles | Medical Director, Clinical Lead, CMO, Medical Affairs Director, MSL, Research Director, Procurement Manager, Medicines Management Lead, Public Health Lead, Partnerships Director | Capture the most commercially useful contacts |
| Geography | United Kingdom, Scotland, Ireland, Western Europe | Match likely delegate origin and regional influence |
| Employee size | 51-200, 201-500, 501-1000, 1001-5000, 5000+ | Covers clinics, trusts, universities, and pharma |
| Keywords | HIV, infectious disease, antiretroviral, drug interactions, clinical research, medical affairs, public health, formulary, patient access | Improves relevance for this specialist congress |
| Company type | Public, private, nonprofit, academic, government | Matches the event’s mixed scientific and institutional audience |
| Revenue range | Use selectively for pharma and healthcare vendors; not essential for public institutions | Helps prioritize larger commercial accounts |
Suggested Apollo Search Logic: Combine HIV OR “infectious disease” OR “medical affairs” OR “clinical research” OR “drug interactions” with industries such as Pharmaceuticals, Hospital & Health Care, Biotechnology, Research, and Government Administration, then filter by seniority (Director, VP, C-level, Head) and geography (United Kingdom, Scotland, Europe).
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| HIV Glasgow official website | Official organizer / event website | Event name, dates (8–11 November 2026), Glasgow location, sponsorship statement, archives, and congress purpose | High |
| Official website programme / general information navigation | Official website structure | Confirmed congress format, educational orientation, and presence of abstract/programme sections | High |
| Official website archive references | Official archived content listing | Historical materials existence (posters and abstracts archive), but not attendance headcount | Medium |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to HIV Drug Therapy Glasgow — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds